SYSTEMATIC REVIEW

REVISED Nitride oxide synthase 3 and klotho gene polymorphisms in the pathogenesis of chronic kidney disease and age-related cognitive impairment: a systematic review and meta-analysis [version 2; peer review: 2 approved]

Atma Gunawan^{1,2}, Jonny Karunia Fajar^{id}², Fredo Tamara^{id}², Aditya Indra Mahendra^{id}², Muhammad Ilmawan^{id}³, Yeni Purnamasari^{id}³, Dessy Aprilia Kartini^{id}³, Eden Suryoiman Winoto^{id}², Efriko Septananda Saifillah², Dewi Sri Wulandari², Pratista Adi Krisna², Ema Dianita Mayasari², Tri Wahyudi Iman Dantara^{id}², Ramadi Satriyo Wicaksono^{id}^{2,4}, Djoko Wahono Soeatmadji⁵

¹Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

²Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

³Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

⁴Department of Internal Medicine, Rumah Sakit Umum Daerah Bangil., Pasuruan, East Java, 67153, Indonesia

⁵Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

V2 First published: 09 Apr 2020, 9:252
<https://doi.org/10.12688/f1000research.22989.1>
 Latest published: 19 Mar 2021, 9:252
<https://doi.org/10.12688/f1000research.22989.2>

Abstract

Background: While it has been known that the development of chronic kidney disease (CKD) and age-related cognitive impairment involves several mediators, the evidence in clinical practice only reveals nitride oxide synthase (NOS) and klotho. However, the evidence for this topic is conflicted. The aim of this study was to assess the role of NOS and klotho single nucleotide polymorphisms (SNPs) in the pathogenesis of CKD and age-related cognitive impairment.

Methods: We performed a meta-analysis during October to December 2019. Paper collection was performed in major scientific websites, and we extracted information of interest from each paper. Data were analyzed using a Z-test with either random or fixed effect model.

Results: Our initial assessment identified NOS3 G894T, NOS3 T786C, NOS3 4b/4a, klotho (KL) G395A, and KL C1818T as the gene candidate for our meta-analysis. Our pooled calculation revealed that NOS3 G894T was associated with the risk of both age-related cognitive

Open Peer Review

Approval Status

	1	2
version 2		
(revision)
19 Mar 2021
version 1
09 Apr 2020
<ol style="list-style-type: none"> 1. Hongliang Zhang^{id}, National Natural Science Foundation of China, Beijing, China 2. Sang Won Park^{id}, Gyeongsang National University, Jinju, South Korea 		

impairment and CKD. Increased susceptibility to age-related cognitive impairment was observed in the GG genotype, and increased risk of CKD was found in patients with a single T allele and TT genotype for *NOS3* nucleotide 894. For *NOS3* 4b/4a, increased risk of CKD was only found in 4a/4a genotype. For *NOS3* T786C, we failed to show the association with both CKD and age-related cognitive impairment. Subsequently, for *KL* G395A, A allele and GA genotype were found to correlate with increased susceptibility to CKD, while its correlation to age-related cognitive impairment was failed to clarify. For *KL* C1818T, our analysis failed to find the correlation with the risk of CKD.

Conclusions: Our results reveal that the *NOS3* G894T gene polymorphism has a crucial role in the pathogenesis of both CKD and age-related cognitive impairment.

Keywords

Nitride oxide synthase, klotho, chronic kidney disease, age-related cognitive impairment

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding authors: Atma Gunawan (atma_gunawan.fk@ub.ac.id), Jonny Karunia Fajar (gembyok@gmail.com)

Author roles: **Gunawan A:** Conceptualization, Data Curation, Methodology, Supervision, Validation; **Fajar JK:** Conceptualization, Methodology, Validation, Writing – Original Draft Preparation; **Tamara F:** Formal Analysis, Investigation, Project Administration, Visualization, Writing – Original Draft Preparation; **Mahendra AI:** Formal Analysis, Investigation, Project Administration, Writing – Original Draft Preparation; **Ilmawan M:** Data Curation, Formal Analysis, Methodology, Project Administration, Software, Visualization, Writing – Original Draft Preparation; **Purnamasari Y:** Conceptualization, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation; **Kartini DA:** Formal Analysis, Investigation, Project Administration, Visualization; **Winoto ES:** Conceptualization, Data Curation, Investigation, Methodology, Supervision, Writing – Original Draft Preparation; **Saifillah ES:** Conceptualization, Funding Acquisition, Investigation, Methodology, Validation, Visualization; **Wulandari DS:** Formal Analysis, Investigation, Project Administration, Supervision, Writing – Original Draft Preparation; **Krisna PA:** Investigation, Methodology, Project Administration, Validation, Visualization; **Mayasari ED:** Conceptualization, Formal Analysis, Investigation, Project Administration, Software, Visualization; **Dantara TWI:** Investigation, Methodology, Visualization; **Wicaksono RS:** Formal Analysis, Investigation, Methodology, Validation, Visualization; **Soeatmadji DW:** Conceptualization, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Gunawan A *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Gunawan A, Fajar JK, Tamara F *et al.* Nitride oxide synthase 3 and klotho gene polymorphisms in the pathogenesis of chronic kidney disease and age-related cognitive impairment: a systematic review and meta-analysis [version 2; peer review: 2 approved] F1000Research 2021, 9:252 <https://doi.org/10.12688/f1000research.22989.2>

First published: 09 Apr 2020, 9:252 <https://doi.org/10.12688/f1000research.22989.1>

REVISED Amendments from Version 1

In this revised version, we provided revision of introduction, results, and discussion. However, the revision does not change the final finding of our study.

Any further responses from the reviewers can be found at the end of the article

Introduction

Aging had remained a challenging topic since the last three decades¹. Some large scale studies have been developed to clarify the precise mechanism of how aging affects the body^{2,3} and also how to prevent this circumstance⁴. This is because aging is a normal condition in human life. This means that this process has to occur in everyone. Recently, to avoid this circumstance, studies have concerned to elucidate aging because aging is known to correlate with age-related diseases including cardiovascular disease⁵, stroke⁶, dementia⁷, and chronic kidney disease (CKD)⁸. Of these, CKD was considered the more serious disease because it was proven to associate with high risk of mortality and poor quality of life⁹. It is widely known that patients with stage V CKD should be treated with regular dialysis and or even renal transplantation¹⁰.

CKD is a fatal disease for most populations¹¹. The investigation regarding the better treatment option for this disease had not provided significant development in developing countries. In the context of aging, this might involve several mediators, including estrogen, androgen, L-arginine, nitride oxide synthase (NOS), and klotho¹². Of these, only NOS and klotho have been well reported in genetic levels and in clinical settings in the context of aging and CKD. Other mediators, during this time, were only proposed as theory or hypothesis. The absence of direct clinical investigation regarding those mediators in the context of aging and CKD led to these mediators being considered as correlated with aging and CKD. The lack of studies investigating aging in clinical practice might be due to the fact that the definition of aging is complex, and it can be difficult to determine the appropriate scope of aging. However, aging is widely to correlate with age-related cognitive impairment¹³. For this reason, in our present study, our investigation only concerned age-related cognitive impairment. Furthermore, investigating the role of NOS and klotho gene polymorphisms in the case of age-related cognitive impairment and CKD was logical and crucial for better understanding concerning the development of aging and CKD. Moreover, due to conflicting reports regarding this topic, a meta-analysis study was required to elucidate the real association.

Our current study, therefore, aimed to perform a meta-analysis concerning the role of NOS and klotho gene polymorphisms in the case of age-related cognitive impairment and CKD. Our present study might provide better understanding on which allele or genotype of NOS and klotho gene polymorphisms are associated with the risk of age-related cognitive impairment and CKD.

Methods

Study design

During the study time frame (October-December 2019), a meta-analysis was conducted to assess the correlation between NOS and klotho gene polymorphisms and the risk of CKD and age-related cognitive impairment. To attain our purpose, we collected papers from PubMed, Embase, Cochrane, and Web of Science. Moreover, to determine the association and effect estimates, data on allele and genotype frequency from selected papers were used to calculate the odds ratio (OR) and 95% confidence interval (95%CI). The protocols in our current study include paper selection, data extraction, quality assessment, and statistical analysis referred to our previous studies^{14–18}, and we also used the checklist of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) to guide the protocols in our study¹⁹. A completed PRISMA checklist for the current study is available (DOI: <https://doi.org/10.6084/m9.figshare.12016782>)²⁰.

Eligibility criteria

To obtain the papers, the following criteria should be met to include the papers in our study: (1) assessing the correlation between NOS and klotho gene variants and the risk of CKD and age-related cognitive impairment; and (2) providing sufficient data for calculation of OR and 95%CI. Furthermore, we excluded the papers if the following reasons were met: (1) irrelevant topic, (2) review, (3) non-standard data presentation, (4) deviation from Hardy-Weinberg equilibrium, and (5) double publication. We managed reference list using EndNote v8 (Thompson Reuters, Eagan, Minnesota) to remove instances of double publication.

Search strategy and data extraction

Papers assessing the association between NOS and klotho gene polymorphisms and the risk of CKD and age-related cognitive impairment were searched in major scientific websites (PubMed, Embase, Cochrane, and Web of Science) up to 5 December 2019. In searching the articles, we restricted the publication language to English. Moreover, to perform a holistic searching, we applied the keywords adapted from medical subject headings (MeSH): [“chronic kidney disease” or “chronic renal failure”] and [“aging” or “age-related cognitive impairment”] and [“nitride oxide synthase” or “NOS”] and [“klotho”]. If we found double publication data, we only included article with the larger sample size. Subsequently, for data extraction, the following information of interest was extracted: (1) first author name; (2) publication year; (3) sample size of case and control, and (4) genotype frequencies of case and control groups.

Assessment of the methodology quality

To assess the quality of each study, a Methodological Index For Non-Randomized Studies (MINORS) scoring system was applied²¹. The MINORS score ranged from 0 to 24 and consisted of 12 items. Each item was assessed as 0 if the item was not reported, 1 if the item was inadequate reported, and 2 if the item was adequate reported. Each study was interpreted as having low quality if the score was less than or equal to 12, moderate if the score was less than or equal

to 16 and more than 12, and high quality if the score was more than 16²¹.

Outcome measure

Our initial searching identified five single nucleotide polymorphisms (SNPs) for included in our meta-analysis: *NOS3* 4b/4a, *NOS3* G894T, *NOS3* T786C, *klotho* (*KL*) G395A, and *KL* C1818T. For age-related cognitive impairment, the SNPs were *NOS3* G894T, *NOS3* T786C, and *KL* G395A. For CKD, the SNPs were *NOS3* 4b4a, *NOS3* G894T, *NOS3* T786C, *KL* G395A, and *KL* C1818T. In each SNP, data analysis was performed in all alleles and genotypes models to assess the correlation and effect estimates. For *NOS3* 4b/4a, the genetic models were 4b vs. 4a; 4a vs. 4b; 4b4b vs. 4b4a+4a4a; 4b4a vs. 4b4b+4a4a; and 4a4a vs. 4b4b+4b4a. For *NOS3* G894T, the genetic models were G vs. T; T vs. G; GG vs. GT+TT; GT vs. GG+TT; and TT vs. GG+GT. For *NOS3* T786C, the genetic models were T vs. C; C vs. T; TT vs. TC+CC; TC vs. TT+CC; and CC vs. TT+TC. For *KL* G395A, the genetic models were as follows: G vs. A; A vs. G; GG vs. GA+AA; GA vs. GG+AA; and AA vs. GG+GA. For *KL* C1818T, the genetic models were C vs. T; T vs. C; CC vs. CT+TT; CT vs. CC+TT; and TT vs. CC+CT.

Statistical analysis

The association and effect estimation between *NOS3* and *KL* gene variants and the risk of CKD and age-related cognitive impairment were determined using a Z-test. The p value of less than 0.05 was considered statistically significant. Moreover, to determine effect estimates, the calculation of pooled OR and 95%CI was performed. Prior to determining the association and effect estimation, to assess the consistency in our meta-analysis, data were analyzed for heterogeneity and potential publication bias. For assessing the heterogeneity, we applied a Q-test. A p-value of less than 0.10 was considered to indicate heterogeneity and data were analyzed using random effect model. Conversely, we used fixed effect model if the p value was more than 0.01. Moreover, for testing the potential for publication bias, Egger's test was employed. A p-value of less than 0.05 was considered as indicating publication bias. All analyses in our present study were performed using Review Manager [Revman Cochrane, London, UK] version 5.3. The cumulative calculation was presented using a forest plot.

Results

Paper selection

Our final paper selection identified 21 papers^{22–42} assessing *NOS3* G894T gene polymorphisms in age-related cognitive impairment; three papers^{22,43,44} assessing *NOS3* T786C gene polymorphisms in age-related cognitive impairment; five papers^{45–49} assessing *KL* G395A gene polymorphisms in age-related cognitive impairment; ten papers^{50–59} evaluating *NOS3* 4b/4a gene polymorphisms in CKD; seven papers^{55–57,59–62} evaluating *NOS3* G894T gene polymorphisms in CKD; three papers^{50,55,63} assessing *NOS3* T786C gene polymorphisms in CKD; six papers^{64–69} assessing *KL* G395A gene polymorphisms in CKD; and three papers^{66–68} assessing *NOS3* C1818T gene polymorphisms in CKD. This number of papers were searched

in PubMed, Embase, Cochrane, and Web of Science; and papers were selected in accordance with inclusion and exclusion criteria. In the initial searching, we identified 10,858 papers. Of those, 10,787 papers were excluded because of irrelevant topic. Moreover, 13 papers were also excluded because of the following reasons: review (seven), not providing required data for calculation of OR and 95%CI (four), and being of low-quality in accordance with NOS assessment (two). A flowchart describing eligibility pathway in our study is provided in [Figure 1](#).

Data synthesis

For age-related cognitive impairment, we identified three SNPs available for meta-analysis calculation, including *NOS3* G894T, *NOS3* T786C, and *KL* G-395A. Of those, the correlation was only found in *NOS3* G894T gene variant. Conversely, we failed to clarify the correlation between the risk of age-related cognitive impairment and *NOS3* T786C and *KL* G395A gene polymorphism. For *NOS3* G894T, we found that increased risk of age-related cognitive impairment ([Figure 2A](#)) was observed in GG genotype of *NOS3* G894T gene polymorphism (OR [95%CI] = 1.14 [1.01 - 1.30], p = 0.0320). On other hands, reduced risk of age-related cognitive impairment ([Figure 2B](#)) was found in GT genotype of *NOS3* G894T gene variant (OR [95%CI] = 0.86 [0.75 - 0.97], p = 0.0170). The summary of the association between age-related cognitive impairment and the gene polymorphisms in *NOS3* and *KL* is given in [Table 1](#).

For *NOS* gene polymorphisms in CKD patients, we identified three SNPs, *NOS3* 4b4a, *NOS3* G894T, and *NOS3* T786C. For *NOS3* 4b4a ([Figure 3A](#)), we found that only the 4a4a genotype was associated with increased risk of CKD (OR [95%CI] = 2.09 [1.43 - 3.06], p < 0.0001). For *NOS3* G894T, we found that the T allele ([Figure 3B](#)) and TT genotype ([Figure 3C](#)) were, by 1.65 and 2.08-fold, respectively, associated with increased risk of CKD. Conversely, the G allele and GG genotype were associated to decreased risk of CKD. Moreover, for *NOS3* T786C, our findings failed to confirm the correlation in CKD patients.

Furthermore, for *klotho* gene polymorphisms in CKD patients, only two SNPs were compatible for our analysis, *KL* G-395A and *KL* C1818T. For *KL* G395A, we included six papers consisting of 550 cases and 1131 controls. Of those, G allele and GG genotype were observed having protective effect against CKD, and A allele ([Figure 4A](#)) and GA genotype ([Figure 4B](#)) were found susceptible for CKD. Moreover, for *klotho* C1818T, we failed to show the correlation in CKD patients. The summary of the correlation between the risk of CKD and the gene polymorphisms in *NOS3* and *KL* is described in [Table 2](#).

Source of heterogeneity

In the case of age-related cognitive impairment, for *NOS3* G894T gene polymorphism, except for TT genotype, the evidence for heterogeneity was found in all genetic models, and therefore we applied random effect model to analyze the data. For *NOS3* T786C, we found no evidence for

Figure 1. PRISMA flowchart of paper selection in our study.

heterogeneity, and therefore fixed effect model was used to analyze the data. For *KL* G395A, the evidence for heterogeneity was observed in all genetic models, except for the GA genotype. Therefore, we used random effect model to analyze the data. We provided the summary of heterogeneity analysis concerning this topic in [Table 1](#).

In the case of CKD, for *NOS3* 4b/4a, evidence for heterogeneity was found in all genetic models, except for the 4a/4a genotype. Therefore, we applied random effect model to analyze the data. Conversely, for the 4a/4a genotype, because it was proven to have no heterogeneity, the analysis was performed using fixed effect model. Subsequently, for *NOS3* G894T, due to the lack of evidence for heterogeneity, we used a fixed effect model to analyze the TT genotype. On other hands, for other genetic models, a random effect model was applied to analyze the data. Moreover, for *NOS3* T786C, due to having the evidence for heterogeneity, we used a random effect model to analyze T and C alleles, the TT genotype, and the TC genotype. For the CC genotype, the association was determined using fixed effect model. Furthermore, for *KL* G395A, all genetic models were analyzed using a random effect model. For *KL* C1818T, a fixed effect model was used to analyze the correlation in all genetic models. We summarize the evidence of heterogeneity concerning the association between the risk of CKD and the gene polymorphisms of *NOS3* and *KL* in [Table 2](#).

Potential publication bias

We applied Egger's test to assess the potency of publication bias among studies. Our analysis revealed that, in the case of age-related cognitive impairment, the publication bias was found in TT genotype of *NOS3* G894T and all genetic models of *NOS3* T786C. Subsequently, in the case of CKD, we found that no publication bias was observed in all genetic models of *NOS3* 4b/4a, *NOS3* G-894T, *NOS3* T-786C, and *KL* G-395A. However, publication bias was found in the C allele, T allele, CC genotype, and CT genotype of *KL* C1818T. The summary of Egger's test in our study is presented in [Table 1](#) for the case of age-related cognitive impairment and [Table 2](#) for the case of CKD.

Discussion

Our current study assessed the correlation between age-related cognitive impairment and the gene polymorphisms in *NOS3* (*NOS3* G894T and *NOS3* T786C). Our results revealed that age-related cognitive impairment was not related to the gene polymorphism of *NOS3* T786C. On other hands, we found that the GG genotype was found to correlate with susceptibility to age-related cognitive impairment, and GT genotype was found to have a protective effect against age-related cognitive impairment. Our findings were consistent with those of a previous study⁷⁰. They also found that GG genotype of *NOS3* G894T was proven to associate with increased the susceptibility to age-related cognitive impairment.

Figure 2. Forest plot of the association between NOS3 G894T gene polymorphism and the risk of age-related cognitive impairment. (A). GG vs. GT+TT; (B). GT vs. GG+TT.

The evidence had confirmed that the polymorphism of NOS3 G894T had been shown to correlate with NO basal production and NOS3 enzyme activity⁷¹. Moreover, elevated NOS3 expression was also found to correlate with increased mitochondrial function in neurons⁷². Therefore, it made sense that the NOS3 G894T gene polymorphism was associated with age-related cognitive impairment as reported in our study. On other hands, we also reported the NOS3 gene

polymorphism in the case of CKD. Our results identified three SNPs available for the calculation of meta-analysis. However, the association with the risk of CKD was only observed in 4b/4a and G894T NOS3 gene polymorphisms. For 4b/4a, our findings revealed that the 4a/4a genotype was associated with increased risk of CKD. For the G894T gene polymorphism, we found that the T allele and TT genotype were observed to correlate with increased risk of CKD. Previous meta-analysis

Table 1. Summary of the association between the risk of age-related cognitive impairment and both *NOS3* and *KL* gene polymorphisms.

SNP	Allele & genotype	NS	Model	Value		OR	95%CI	pHet	pE	p-value
				Case (%)	Control (%)					
<i>NOS3</i> G894T	G vs. T	21	Random	75.3	75.1	1.08	0.99 - 1.18	0.0460	0.1210	0.0840
	T vs. G	21	Random	24.7	24.9	0.92	0.85 - 1.01	0.0460	0.1210	0.0840
	GG vs. GT+TT	21	Random	58.2	57.1	1.14	1.01 - 1.30	0.0100	0.1890	0.0320
	GT vs. GG+TT	21	Random	34.2	36.0	0.86	0.75 - 0.97	0.0060	0.2010	0.0170
	TT vs. GG+GT	21	Fixed	7.6	6.9	1.04	0.89 - 1.22	0.6770	<0.0001	0.6100
<i>NOS3</i> T786C	T vs. C	3	Fixed	75.7	80.2	0.93	0.81 - 1.07	0.6130	<0.0001	0.3010
	C vs. T	3	Fixed	24.3	19.8	1.08	0.94 - 1.24	0.6130	<0.0001	0.3010
	TT vs. TC+CC	3	Fixed	60.0	66.1	0.94	0.79 - 1.13	0.4960	<0.0001	0.5120
	TC vs. TT+CC	3	Fixed	31.3	28.1	1.00	0.84 - 1.19	0.5520	<0.0001	0.9980
	CC vs. TT+TC	3	Fixed	8.7	5.8	1.20	0.88 - 1.64	0.6970	<0.0001	0.2500
<i>KL</i> G395A	G vs. A	5	Random	84.6	84.7	0.93	0.73 - 1.18	0.0160	0.2210	0.5350
	A vs. G	5	Random	15.4	15.3	1.08	0.85 - 1.37	0.0160	0.2210	0.5350
	GG vs. GA+AA	5	Random	70.3	71.1	0.92	0.72 - 1.16	0.0450	0.2070	0.4730
	GA vs. GG+AA	5	Fixed	28.6	27.2	1.08	0.93 - 1.26	0.2520	0.1020	0.3060
	AA vs. GG+GA	3	Random	1.1	1.7	1.05	0.34 - 3.27	0.0280	0.8490	0.9270

SNP, single nucleotide polymorphism; NS, number of studies; OR, odd ratio; pHet, p heterogeneity; pE, p Egger.

regarding this topic had been conducted^{73,74}. However, our current study provided the update, and our current results were consistent with previous studies. Additionally, supporting our results, a previous study confirmed that the TT genotype and T allele of the G894T polymorphism, but not 4b/4a, were associated with the lower level of NO in circulation⁷⁵ and enzyme activity⁷⁶. Furthermore, lower NO levels compared to control was found in patients with CKD⁷⁷, although increased levels of NO were observed in CKD patients after dialysis⁷⁸. The similarity of the dominant role of the *NOS3* G894T gene polymorphism, both in age-related cognitive impairment and CKD, might explain the bridging mechanism between aging and CKD with NO involvement, in the context of gene-disease and gene-gene interactions.

The precise mechanism of NO in age-related cognitive impairment and CKD is undefined. However, some speculation may be proposed. Briefly, NO plays a significant role in cell growth and renal vasculature. It is widely known that NO plays as a vascular vasodilator. Additionally, NO may also inhibit the growth of mesangial cell and matrix production. The decreased level of NO in aging may cause to renal vasoconstriction, sodium retention, and increased matrix production and mesangial fibrosis⁷⁹. Moreover, NO isoforms are observed at higher levels in the medullary region than other regions. On other hands, in the renal cortex, the levels of NO isoforms

are reduced. Therefore, they may contribute to the reduced perfusion of renal cortex in the elderly⁸⁰. The precise pathway of decreased level of NO in elderly remains confusing. However, several mechanisms have been proposed. First, oxidative stress is known to increase with age. It may stimulate to decrease the key factors for normal NO production, for example tetrahydrobiopterin⁸¹. Second, L-arginine is known to be key for the production of NO. The availability of this substrate may decline with advance age. While L-arginine is not an essential amino acid, a study had reported that the level of L-arginine was observed decreased in older rats. This indicates that L-arginine may play a crucial role as an essential amino acid in advance age, and therefore sufficient dietary intake may be required to maintain the NO production⁷⁹. Moreover, L-arginine level in circulation was also found to be significantly lower in patients with CKD than controls, and it was consistent with the level of NO⁷⁷. This suggested the pivotal role of L-arginine and NO in aging and CKD. Third, it is known that NOS is degraded by asymmetric dimethyl arginine (ADMA). Previous study in a rat model revealed that ADMA levels were observed higher in advance age. This suggests that elevated ADMA level may increase the degradation of NOS and cause lower NO production⁸². Supporting this explanation, a study found that ADMA levels in circulation were higher in CKD patients than control, was contrary to the levels of NO and L-arginine⁷⁷. This explanation might bridge the mechanism

Figure 3. Forest plot of the association between NOS3 gene polymorphism and the risk of CKD. A). 4a4a vs. 4b4b+4b4a of NOS3 4b/4a; B). T vs. G of NOS3 G-894T; C). TT vs. GG+GT of NOS3 G-894T.

between NO, aging, and CKD as reported in our present study.

While klotho was considered as one of the important mediators in aging, our findings failed to confirm the association between the *KL* G395A gene polymorphism and risk of age-related cognitive impairment. However, due to limited sample size, further investigation to assess this correlation was required. On other hands, correlating to CKD, our searching strategy identified *KL* G395A and C1818T as available for

meta-analysis calculation. Our analysis confirmed that the association with CKD was only found in klotho G-395A gene polymorphism. We revealed that the A allele and GA genotype were correlated with increased risk of CKD. Until now, we have failed to obtain a systematic review or meta-analysis in the topic of either klotho in aging or in CKD. Therefore, a direct comprehensive comparison was unable to perform. However, it had been reported that α -klotho protein was related to the G395A polymorphism⁸³, and α -klotho protein in circulation was also proven by a large scale meta-analysis study

Figure 4. Forest plot of the association between *KL* G395A gene polymorphism and the risk of CKD. (A). A vs. G of *KL* G-395A; (B). GA vs. GG+AA of *KL* G395A.

to have positive correlation with renal function⁸⁴. It means that the lower level of klotho protein, the lower the renal function. Therefore, it might explain the results of our study confirming that the G395A gene polymorphism was correlated with the risk of CKD.

The theory explaining the exact mechanism between klotho, aging, and CKD is complicated and may involve genes, proteins, and target organ damage. At the genetic level, *KL* is expressed in limited tissues and cell types, and the highest expression is observed in distal convoluted tubules in the kidney and choroid plexus in the brain⁸⁵. Therefore, the klotho protein exists in two forms. One is the trans-membrane form expressed primarily in renal tubular cells, and the other is the secreted form circulating in the blood⁸⁶. Klotho protein level has been shown to correlate with human longevity⁸⁷. However, in advance age, the level of klotho protein is decreased⁸⁸, and this decreased level is associated with increased oxidative stress, proinflammatory cytokine production, and activation of endothelin signal transduction⁸⁹. Furthermore, the interaction between klotho and CKD is complex. It may involve specific signaling axis, defined as the klotho-fibroblast growth factor-23 (FGF23) signaling axis. Briefly, when the body has excessive amounts of phosphate, FGF23 is secreted. Subsequently, in the kidney, FGF23 may promote phosphate excretion into urine and suppress vitamin D synthesis. Consequently, it may induce negative phosphate

balance. However, in this circumstance, FGF23 requires klotho to bind and activate FGF receptors. After FGF receptor activation by klotho, FGF23 binds to its receptor⁹⁰. There are four type of receptors for FGF23, such as FGFR1, FGFR2, FGFR3, and FGFR4. However, FGFR1 is the dominant receptor playing in this signaling pathway⁹¹. When the binding between FGF23 and FGFR1 occurs, it may activate extracellular signals - regulated kinase (ERK) and serum/glucocorticoid-regulated kinase (SGK) signals. Furthermore, the phosphorylation of the Na^+/H^+ exchange regulatory cofactor (NHERF)-1 by SGK-1 was established to down-regulate membrane expression of sodium phosphate co-transporter NaPi-2a. Consequently, it may cause increasing urinary phosphate excretion⁹². On other hands, the binding between FGF23 and FGFR1 may also suppress the expression of 1α -hydroxylase, the enzyme responsible for the production of $1,25(\text{OH})_2\text{D}$. Therefore, it may participate to systemic mineral homeostasis and regulate the excretion of phosphate⁹³. In this context, if the level of klotho is decreased, it may lead to lower level of FGF23 and stimulate to hyperphosphatemia, one of the pathological states widely observed in CKD⁹⁴. Moreover, it was also reported that the level of klotho protein was found to decline and it was also accompanied by renal insufficiency in patients with CKD⁹⁵. Additionally, the gene-interaction studies also revealed that the decline of klotho level in subjects with CKD involved specific phenotypes, suggesting that klotho was independently

Table 2. Summary of the association between the risk of CKD and both NOS3 and KL gene polymorphisms.

SNP	Allele & genotype	NS	Model	Value		OR	95%CI	pHet	pE	p-value
				Case (%)	Control (%)					
NOS3 4b4a	4b vs. 4a	10	Random	83.5	86.4	0.80	0.60 - 1.07	<0.0001	0.4140	0.1300
	4a vs. 4b	10	Random	16.5	13.6	1.25	0.94 - 1.68	<0.0001	0.4140	0.1300
	4b4b vs. 4b4a+4a4a	10	Random	70.6	74.8	0.81	0.59 - 1.12	<0.0001	0.4490	0.2000
	4b4a vs. 4b4b+4a4a	10	Random	25.7	23.1	1.13	0.86 - 1.48	<0.0001	0.3610	0.3950
	4a4a vs. 4b4b+4b4a	9	Fixed	3.7	2.1	2.09	1.43 - 3.06	0.1170	0.5110	<0.0001
NOS3 G894T	G vs. T	7	Random	69.1	80.2	0.61	0.45 - 0.82	0.0030	0.3310	0.0010
	T vs. G	7	Random	30.9	19.8	1.65	1.22 - 2.23	0.0030	0.3310	0.0010
	GG vs. GT+TT	7	Random	51.0	66.0	0.59	0.42 - 0.84	0.0160	0.3570	0.0030
	GT vs. GG+TT	7	Random	36.3	28.3	1.29	0.87 - 1.93	0.0020	0.4470	0.2070
	TT vs. GG+GT	6	Fixed	12.7	5.7	2.08	1.46 - 2.97	0.3930	0.1010	<0.0001
NOS3 T786C	T vs. C	3	Random	76.4	73.5	0.80	0.45 - 1.45	0.0040	0.4720	0.4710
	C vs. T	3	Random	23.6	26.5	1.24	0.69 - 2.25	0.0040	0.4720	0.4710
	TT vs. TC+CC	3	Random	59.2	56.1	0.81	0.40 - 1.63	0.0090	0.5460	0.5570
	TC vs. TT+CC	3	Random	34.4	34.9	1.21	0.66 - 2.22	0.0290	0.4520	0.5340
	CC vs. TT+TC	3	Fixed	6.4	9.0	1.07	0.59 - 1.94	0.3240	0.2080	0.8280
KL G395A	G vs. A	6	Random	74.2	84.4	0.40	0.20 - 0.77	<0.0001	0.7720	0.0070
	A vs. G	6	Random	25.8	15.6	2.53	1.29 - 4.96	<0.0001	0.7720	0.0070
	GG vs. GA+AA	6	Random	56.0	70.0	0.36	0.17 - 0.76	<0.0001	0.8660	0.0070
	GA vs. GG+AA	6	Random	36.4	28.7	2.08	1.16 - 3.72	<0.0001	0.6230	0.0140
	AA vs. GG+GA	4	Random	7.6	1.2	2.96	0.84 - 10.42	0.0690	0.9400	0.0910
KL C1818T	C vs. T	3	Fixed	78.2	81.8	0.96	0.76 - 1.21	0.7020	<0.0001	0.7160
	T vs. C	3	Fixed	21.8	18.2	1.05	0.83 - 1.32	0.7020	<0.0001	0.7160
	CC vs. CT+TT	3	Fixed	59.3	65.4	0.96	0.72 - 1.27	0.7000	<0.0001	0.7600
	CT vs. CC+TT	3	Fixed	38.0	33.0	1.03	0.77 - 1.37	0.5620	<0.0001	0.8530
	TT vs. CC+T	2	Fixed	2.8	1.7	1.05	0.42 - 2.63	0.1800	1.0130	0.9130

SNP, single nucleotide polymorphism; NS, number of studies; OR, odd ratio; pHet, p heterogeneity; pE, p Egger.

involved in the pathogenesis of CKD^{85,95}. This explanation might be a benchmark for the results of our study that klotho is an important mediator involved in the development of aging and CKD.

Our results have identified SNPs potentially involved in the pathogenesis of age-related cognitive impairment and CKD. Therefore, our current findings might help to elucidate the precise mechanism of aging and CKD in the perspective of clinical evidence and gene-disease interaction.

Despite the limitations of our study, our findings might be as the initial step to develop further investigation for the management of aging and CKD. However, more studies on this topic are required to establish further due to some limitations, especially the wide context of aging that may make it difficult to conduct analysis and also may lead to high potency for bias.

In our current study, several limitations were noted. First, some factors that might influence NOS3 and klotho level

including multiple sclerosis⁹⁶, asthma⁹⁷, chronic obstructive pulmonary disease⁹⁸, and cardiovascular disease⁵ were not controlled for. Second, several potential confounding factors, mediators, and compensatory factors that might implicate the final findings of our study were not analyzed. Third, due to relatively small sample size, our findings should be interpreted with caution, considering the potency for bias. Fourth, most of study design in our included studies were cross-sectional. Thus, further studies with involving better study design might be required.

Conclusion

Our present study has identified that *NOS3* G894T plays an important role in the pathogenesis of both age-related cognitive impairment and CKD. On other hand, while we have found an association between *KL* G395A gene polymorphism and the risk of CKD, its correlation with age-related cognitive impairment has not been clarified. Our current study may contribute to better understanding regarding

the role of *NOS3* and *KL* in the pathogenesis of age-related cognitive impairment and CKD.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Reporting guidelines

Figshare: PRISMA checklist for 'Nitride oxide synthase 3 and klotho gene polymorphisms in the pathogenesis of chronic kidney disease and age-related cognitive impairment: a systematic review and meta-analysis'. <https://doi.org/10.6084/m9.figshare.12016782>²⁰.

Acknowledgements

We thank to DSKF Publishing Campus & Lembaga Pengelola Dana Pendidikan (LPDP) Republik Indonesia.

References

1. Curb JD, Guralnik JM, LaCroix AZ, et al.: **Effective aging. Meeting the challenge of growing older.** *J Am Geriatr Soc.* 1990; **38**(7): 827–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Zhou J, Xue Z, He HN, et al.: **Resveratrol delays postovulatory aging of mouse oocytes through activating mitophagy.** *Aging (Albany NY).* 2019; **11**(23): 11504–11519.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Liu H, Wang H, Yang S, et al.: **Downregulation of miR-542-3p promotes osteogenic transition of vascular smooth muscle cells in the aging rat by targeting BMP7.** *Hum Genomics.* 2019; **13**(1): 67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Choudhary A, Pathak A, Manickam P, et al.: **Effect of Yoga versus Light Exercise to Improve Well-Being and Promote Healthy Aging among Older Adults in Central India: A Study Protocol for a Randomized Controlled Trial.** *Geriatrics (Basel).* 2019; **4**(4): 64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Donate-Correa J, Martin-Nunez E, Martinez-Sanz R, et al.: **Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease.** *J Cell Mol Med.* 2016; **20**(1): 128–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Yousufuddin M, Young N: **Aging and ischemic stroke.** *Aging (Albany NY).* 2019; **11**(9): 2542–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Irwin K, Sexton C, Daniel T, et al.: **Healthy Aging and Dementia: Two Roads Diverging in Midlife?** *Front Aging Neurosci.* 2018; **10**: 275.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Nitta K, Okada K, Yanai M, et al.: **Aging and chronic kidney disease.** *Kidney Blood Press Res.* 2013; **38**(1): 109–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Jesky MD, Dutton M, Dasgupta I, et al.: **Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study.** *PLoS One.* 2016; **11**(11): e0165675.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Levin A, Hemmelgarn B, Culleton B, et al.: **Guidelines for the management of chronic kidney disease.** *CMAJ.* 2008; **179**(11): 1154–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Wright Nunes J, Roney M, Kerr E, et al.: **A diagnosis of chronic kidney disease: despite fears patients want to know early.** *Clin Nephrol.* 2016; **86**(2): 78–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Baylis C: **Sexual dimorphism, the aging kidney, and involvement of nitric oxide deficiency.** *Semin Nephrol.* 2009; **29**(6): 569–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Murrman DL: **The Impact of Age on Cognition.** *Semin Hear.* 2015; **36**(3): 111–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Daryanto B, Purnomo BB, Gunawan A, et al.: **The association between vitamin D receptor gene polymorphisms and the risk of nephrolithiasis: A meta-analysis.** *Meta Gene.* 2019; 100628.
[Publisher Full Text](#)
15. Fajar JK, Pikir BS, Sidarta EP, et al.: **The Gene Polymorphism of Angiotensin-Converting Enzyme Intron Deletion and Angiotensin-Converting Enzyme G2350A in Patients With Left Ventricular Hypertrophy: A Meta-analysis.** *Indian Heart J.* 2019; **71**(3): 199–206.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Fajar JK, Susanti M, Pikir BS, et al.: **The association between angiotensin II type 1 receptor A1166C gene polymorphism and the risk of essential hypertension: a meta-analysis.** *Springer.* 2019.
[Publisher Full Text](#)
17. Fajar JK, Pikir BS, Sidarta EP, et al.: **The genes polymorphism of angiotensinogen (AGT) M235T and AGT T174M in patients with essential hypertension: A meta-analysis.** *Gene Reports.* 2019; 100421.
[Publisher Full Text](#)
18. Fajar JK, Mahendra AI, Tamara F, et al.: **The Association Between Complete Blood Count and the Risk of Coronary Heart Disease.** *Türkiye Klinikleri Tıp Bilimleri Dergisi.* 2019; **39**(1): 56–64.
[Publisher Full Text](#)
19. Moher D, Liberati A, Tetzlaff J, et al.: **Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.** *PLoS Med.* 2009; **6**(7): e1000097.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Fajar J: **PRISMA: Nitride oxide synthase 3 and klotho gene polymorphisms in the pathogenesis of chronic kidney disease and age-related cognitive impairment: a meta-analysis.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.12016782.v1>
21. Slim K, Nini E, Forestier D, et al.: **Methodological index for non-randomized studies (minors): development and validation of a new instrument.** *ANZ J Surg.* 2003; **73**(9): 712–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Akomolafe A, Lunetta KL, Erlich PM, et al.: **Genetic association between endothelial nitric oxide synthase and Alzheimer disease.** *Clin Genet.* 2006; **70**(1): 49–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Azizi Z, Noroozian M, Kaini-Moghaddam Z, et al.: **Association between NOS3 gene G894T polymorphism and late-onset Alzheimer disease in a sample from Iran.** *Alzheimer Dis Assoc Disord.* 2010; **24**(2): 204–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Blomqvist ME, Reynolds C, Katzov H, et al.: **Towards compendia of negative genetic association studies: an example for Alzheimer disease.** *Hum Genet.* 2006; **119**(1–2): 29–37.
[PubMed Abstract](#) | [Publisher Full Text](#)

25. Crawford F, Freeman M, Abdullah L, *et al.*: **No association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States.** *Ann Neurol.* 2000; **47**(5): 687.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Dahiyat M, Cumming A, Harrington C, *et al.*: **Association between Alzheimer's disease and the NOS3 gene.** *Ann Neurol.* 1999; **46**(4): 664–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Emahazion T, Feuk L, Jobs M, *et al.*: **SNP association studies in Alzheimer's disease highlight problems for complex disease analysis.** *Trends Genet.* 2001; **17**(7): 407–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Ferlazzo N, Gorgone G, Caccamo D, *et al.*: **The 894G > T (Glu298Asp) variant in the endothelial NOS gene and MTHFR polymorphisms influence homocysteine levels in patients with cognitive decline.** *Neuromolecular Med.* 2011; **13**(3): 167–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Giedraitis V, Kilander L, Degerman-Gunnarsson M, *et al.*: **Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men.** *Dement Geriatr Cogn Disord.* 2009; **27**(1): 59–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Guidi I, Galimberti D, Venturini E, *et al.*: **Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients.** *Neurobiol Aging.* 2005; **26**(6): 789–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Higuchi S, Ohta S, Matsushita S, *et al.*: **NOS3 polymorphism not associated with Alzheimer's disease in Japanese.** *Ann Neurol.* 2000; **48**(4): 685.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Kálmán J, Juhász A, Rimanóczy A, *et al.*: **The nitric oxide synthase-3 codon 298 polymorphism is not associated with late-onset sporadic Alzheimer's dementia and Lewy body disease in a sample from Hungary.** *Psychiatr Genet.* 2003; **13**(4): 201–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Kunugi H, Akahane A, Ueki A, *et al.*: **No evidence for an association between the Glu298Asp polymorphism of the NOS3 gene and Alzheimer's disease.** *J Neural Transm (Vienna).* 2000; **107**(8–9): 1081–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Li H, Wetten S, Li L, *et al.*: **Candidate single-nucleotide polymorphisms from a genome-wide association study of Alzheimer disease.** *Arch Neurol.* 2008; **65**(1): 45–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Monastero R, Cefalù AB, Camarda C, *et al.*: **No association between Glu298Asp endothelial nitric oxide synthase polymorphism and Italian sporadic Alzheimer's disease.** *Neurosci Lett.* 2003; **341**(3): 229–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Sánchez-Guerra M, Combarros O, Alvarez-Arcaya A, *et al.*: **The Glu298Asp polymorphism in the NOS3 gene is not associated with sporadic Alzheimer's disease.** *J Neurol Neurosurg Psychiatry.* 2001; **70**(4): 566–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Singleton AB, Gibson AM, McKeith IG, *et al.*: **Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies.** *Neurosci Lett.* 2001; **303**(1): 33–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Styczynska M, Religa D, Pfeffer A, *et al.*: **Simultaneous analysis of five genetic risk factors in Polish patients with Alzheimer's disease.** *Neurosci Lett.* 2003; **344**(2): 99–102.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Tedde A, Nacmias B, Cellini E, *et al.*: **Lack of association between NOS₃ polymorphism and Italian sporadic and familial Alzheimer's disease.** *J Neurol.* 2002; **249**(1): 110–1.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Wang B, Tan S, Yang Z, *et al.*: **Association between Alzheimer's disease and the NOS3 gene Glu298Asp polymorphism in Chinese.** *J Mol Neurosci.* 2008; **34**(2): 173–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Yang Ze LS, Jin Feng, Lv Zeping, *et al.*: **Association of polymorphism of the endothelial nitric oxide synthase gene with Alzheimer disease.** *Chinese J Geriatrics.* 2004; **2004**(7): 468–71.
[Reference Source](#)
42. Zhou YT, Zhang ZX, Zhang JW: **Association Between Nitric Oxide Synthase-3 Polymorphism and Alzheimer's Disease in Chinese Han Population.** *Chinese Journal of Clinical Neurosciences.* 2006; **7**.
[Reference Source](#)
43. Hashimoto M, Miyai N, Hattori S, *et al.*: **Age and gender differences in the influences of eNOS T-786C polymorphism on arteriosclerotic parameters in general population in Japan.** *Environ Health Prev Med.* 2016; **21**(4): 274–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Venturini E, Galimberti D, Lovati C, *et al.*: **The T-786C NOS3 polymorphism in Alzheimer's disease: association and influence on gene expression.** *Neurosci Lett.* 2005; **382**(3): 300–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Abulizi P, Zhou XH, Keyimu K, *et al.*: **Correlation between KLOTHO gene and mild cognitive impairment in the Uyghur and Han populations of Xinjiang.** *Oncotarget.* 2017; **8**(43): 75174–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Hao Q, Ding X, Gao L, *et al.*: **G-395A polymorphism in the promoter region of the KLOTHO gene associates with reduced cognitive impairment among the oldest old.** *Age (Dordr).* 2016; **38**(1): 7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Hao Q, Wang Y, Ding X, *et al.*: **G-395A polymorphism in the promoter region of the KLOTHO gene associates with frailty among the oldest-old.** *Sci Rep.* 2018; **8**(1): 6735.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Kim Y, Kim JH, Nam YJ, *et al.*: **Klotho is a genetic risk factor for ischemic stroke caused by cardioembolism in Korean females.** *Neurosci Lett.* 2006; **407**(3): 189–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Shimokata H, Ando F, Fukukawa Y, *et al.*: **Klotho gene promoter polymorphism and cognitive impairment.** *Geriatr Gerontol Int.* 2006; **6**: 136–41.
[Publisher Full Text](#)
50. Asakimori Y, Yorioka N, Yamamoto I, *et al.*: **Endothelial nitric oxide synthase intron 4 polymorphism influences the progression of renal disease.** *Nephron.* 2001; **89**(2): 219–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Bellini MH, Figueira MN, Piccoli MF, *et al.*: **Association of endothelial nitric oxide synthase gene intron 4 polymorphism with end-stage renal disease.** *Nephrology (Carlton).* 2007; **12**(3): 289–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Buraczynska M, Ksiazek P, Zaluska W, *et al.*: **Endothelial nitric oxide synthase gene intron 4 polymorphism in patients with end-stage renal disease.** *Nephrol Dial Transplant.* 2004; **19**(9): 2302–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Elshamaa MF, Sabry S, Badr A, *et al.*: **Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with chronic kidney disease.** *Blood Coagul Fibrinolysis.* 2011; **22**(6): 487–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Lamnissou K, Ziogiannis P, Trygonis S, *et al.*: **Evidence for association of endothelial cell nitric oxide synthase gene polymorphism with earlier progression to end-stage renal disease in a cohort of Hellens from Greece and Cyprus.** *Genet Test.* 2004; **8**(3): 319–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Marson BP, Dickel S, Ishizawa MH, *et al.*: **Endothelial nitric oxide genotypes and haplotypes are not associated with end-stage renal disease.** *DNA Cell Biol.* 2011; **30**(1): 55–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Nagase S, Suzuki H, Wang Y, *et al.*: **Association of eNOS gene polymorphisms with end stage renal diseases.** *Mol Cell Biochem.* 2003; **244**(1–2): 113–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Noiri E, Satoh H, Taguchi J, *et al.*: **Association of eNOS Glu298Asp polymorphism with end-stage renal disease.** *Hypertension.* 2002; **40**(4): 535–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Tripathi G, Sharma RK, Baburaj VP, *et al.*: **Genetic risk factors for renal failure among north Indian ESRD patients.** *Clin Biochem.* 2008; **41**(7–8): 525–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Vasudevan R, Ismail P, Jaafar N, *et al.*: **Analysis of human bradykinin receptor gene and endothelial nitric oxide synthase gene polymorphisms in end-stage renal disease among Malaysians.** *Balkan J Med Genet.* 2014; **17**(1): 37–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. El-Din Bessa SS, Hamdy SM: **Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients.** *Ren Fail.* 2011; **33**(9): 878–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Kerkeni M, Letaief A, Achour A, *et al.*: **Endothelial nitric oxide synthetase, methylenetetrahydrofolate reductase polymorphisms, and cardiovascular complications in Tunisian patients with nondiabetic renal disease.** *Clin Biochem.* 2009; **42**(10–11): 958–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Tang FY, Liu FY, Xie XW: **Association of angiotensin-converting enzyme and endothelial Nitric Oxide synthase gene polymorphisms with vascular disease in ESRD patients in a Chinese population.** *Mol Cell Biochem.* 2008; **319**(1–2): 33–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Zsom M, Fulop T, Zsom L, *et al.*: **Genetic polymorphisms and the risk of progressive renal failure in elderly Hungarian patients.** *Hemodial Int.* 2011; **15**(4): 501–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Elghoroury EA, Fadel FI, Elshamaa MF, *et al.*: **Klotho G-395A gene polymorphism: impact on progression of end-stage renal disease and development of cardiovascular complications in children on dialysis.** *Pediatr Nephrol.* 2018; **33**(6): 1019–27.
[PubMed Abstract](#) | [Publisher Full Text](#)

65. Kim Y, Jeong SJ, Lee HS, *et al.*: Polymorphism in the promoter region of the *klotho* gene (G-395A) is associated with early dysfunction in vascular access in hemodialysis patients. *Korean J Intern Med.* 2008; **23**(4): 201–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Ko GJ, Lee YM, Lee EA, *et al.*: The association of *Klotho* gene polymorphism with the mortality of patients on maintenance dialysis. *Clin Nephrol.* 2013; **80**(4): 263–9. [PubMed Abstract](#) | [Publisher Full Text](#)
67. Nazarian A, Hasankhani M, Aghajany-Nasab M, *et al.*: Association Between *Klotho* Gene Polymorphism and Markers of Bone Metabolism in Patients Receiving Maintenance Hemodialysis in Iran. *Iran J Kidney Dis.* 2017; **11**(6): 456–60. [PubMed Abstract](#)
68. Shimoyama Y, Taki K, Mitsuda Y, *et al.*: *KLOTHO* gene polymorphisms G-395A and C1818T are associated with low-density lipoprotein cholesterol and uric acid in Japanese hemodialysis patients. *Am J Nephrol.* 2009; **30**(4): 383–8. [PubMed Abstract](#) | [Publisher Full Text](#)
69. Zeng QY, Xia ZY, Tong YS, *et al.*: Association of *klotho* gene polymorphism and the regulation of calcium-phosphate metabolism disorders in patients with end-stage renal disease. *Nephrology (Carlton).* 2019; **24**(10): 1001–8. [PubMed Abstract](#) | [Publisher Full Text](#)
70. Liu S, Zeng F, Wang C, *et al.*: The nitric oxide synthase 3 G894T polymorphism associated with Alzheimer's disease risk: a meta-analysis. *Sci Rep.* 2015; **5**: 13598. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Veldman BA, Spiering W, Doevendans PA, *et al.*: The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. *J Hypertens.* 2002; **20**(10): 2023–7. [PubMed Abstract](#) | [Publisher Full Text](#)
72. Kapoor S: Close association between polymorphisms of the nitric oxide synthetase 3 gene and neurological disorders other than stroke. *Int J Gen Med.* 2012; **5**: 431–2. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. Yun Z, Yu-Ping Y, Zong-Wu T, *et al.*: Association of endothelial nitric oxide synthase gene polymorphisms with end-stage renal disease: a systematic review and meta-analysis. *Ren Fail.* 2014; **36**(6): 987–93. [PubMed Abstract](#) | [Publisher Full Text](#)
74. Zhou TB, Yin SS: Association of endothelial nitric oxide synthase Glu298Asp gene polymorphism with the risk of end-stage renal disease. *Ren Fail.* 2013; **35**(4): 573–8. [PubMed Abstract](#) | [Publisher Full Text](#)
75. Angeline T, Isabel W, Tsongalis GJ: Endothelial nitric oxide gene polymorphisms, nitric oxide production and coronary artery disease risk in a South Indian population. *Exp Mol Pathol.* 2010; **89**(3): 205–8. [PubMed Abstract](#) | [Publisher Full Text](#)
76. Seckin Y, Yigit A, Yesilada E, *et al.*: Association of eNOS Gene Polymorphisms G894T and T-786C with Risk of Hepatorenal Syndrome. *Gastroenterol Res Pract.* 2016; **2016**: 2579626. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Reddy YS, Kiranmayi VS, Bitla AR, *et al.*: Nitric oxide status in patients with chronic kidney disease. *Indian J Nephrol.* 2015; **25**(5): 287–91. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Meenakshi SR, Agarwal R: Nitric oxide levels in patients with chronic renal disease. *J Clin Diagn Res.* 2013; **7**(7): 1288–90. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. Baylis C: Sexual dimorphism in the aging kidney: differences in the nitric oxide system. *Nat Rev Nephrol.* 2009; **5**(7): 384–96. [PubMed Abstract](#) | [Publisher Full Text](#)
80. Llorens S, Fernandez AP, Nava E: Cardiovascular and renal alterations on the nitric oxide pathway in spontaneous hypertension and ageing. *Clin Hemorheol Microcirc.* 2007; **37**(1–2): 149–56. [PubMed Abstract](#)
81. Delp MD, Behnke BJ, Spier SA, *et al.*: Ageing diminishes endothelium-dependent vasodilatation and tetrahydrobiopterin content in rat skeletal muscle arterioles. *J Physiol.* 2008; **586**(4): 1161–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Xiong Y, Yuan LW, Deng HW, *et al.*: Elevated serum endogenous inhibitor of nitric oxide synthase and endothelial dysfunction in aged rats. *Clin Exp Pharmacol Physiol.* 2001; **28**(10): 842–7. [PubMed Abstract](#) | [Publisher Full Text](#)
83. Rhee EJ, Oh KW, Yun EJ, *et al.*: Relationship between polymorphisms G395A in promoter and C1818T in exon 4 of the *KLOTHO* gene with glucose metabolism and cardiovascular risk factors in Korean women. *J Endocrinol Invest.* 2006; **29**(7): 613–8. [PubMed Abstract](#) | [Publisher Full Text](#)
84. Wang Q, Su W, Shen Z, *et al.*: Correlation between Soluble α -*Klotho* and Renal Function in Patients with Chronic Kidney Disease: A Review and Meta-Analysis. *Biomed Res Int.* 2018; **2018**: 9481475. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85. Hu MC, Kuro-o M, Moe OW: *Klotho* and chronic kidney disease. *Contrib Nephrol.* 2013; **180**: 47–63. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. Kuro-o M: *Klotho* and aging. *Biochim Biophys Acta.* 2009; **1790**(10): 1049–58. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Semba RD, Cappola AR, Sun K, *et al.*: Plasma *klotho* and mortality risk in older community-dwelling adults. *J Gerontol A Biol Sci Med Sci.* 2011; **66**(7): 794–800. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Crasto CL, Semba RD, Sun K, *et al.*: Relationship of low-circulating “anti-aging” *klotho* hormone with disability in activities of daily living among older community-dwelling adults. *Rejuvenation Res.* 2012; **15**(3): 295–301. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Zuo Z, Lei H, Wang X, *et al.*: Aging-related kidney damage is associated with a decrease in *klotho* expression and an increase in superoxide production. *Age (Dordr).* 2011; **33**(3): 261–74. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Kuro-o M: Overview of the FGF23-*Klotho* axis. *Pediatr Nephrol.* 2010; **25**(4): 583–90. [PubMed Abstract](#) | [Publisher Full Text](#)
91. Urakawa I, Yamazaki Y, Shimada T, *et al.*: *Klotho* converts canonical FGF receptor into a specific receptor for FGF23. *Nature.* 2006; **444**(7120): 770–4. [PubMed Abstract](#) | [Publisher Full Text](#)
92. Erben RG, Andrukhova O: FGF23-*Klotho* signaling axis in the kidney. *Bone.* 2017; **100**: 62–8. [PubMed Abstract](#) | [Publisher Full Text](#)
93. Zou D, Wu W, He Y, *et al.*: The role of *klotho* in chronic kidney disease. *BMC Nephrol.* 2018; **19**(1): 285. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
94. Hruska KA, Mathew S, Lund R, *et al.*: Hyperphosphatemia of chronic kidney disease. *Kidney Int.* 2008; **74**(2): 148–57. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
95. Hu MC, Shi M, Zhang J, *et al.*: *Klotho* deficiency causes vascular calcification in chronic kidney disease. *J Am Soc Nephrol.* 2011; **22**(1): 124–36. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
96. AlFadhli S, Mohammed EM, Al Shubaili A: Association analysis of nitric oxide synthases: NOS1, NOS2A and NOS3 genes, with multiple sclerosis. *Ann Hum Biol.* 2013; **40**(4): 368–75. [PubMed Abstract](#) | [Publisher Full Text](#)
97. Leung TF, Liu EK, Tang NL, *et al.*: Nitric oxide synthase polymorphisms and asthma phenotypes in Chinese children. *Clin Exp Allergy.* 2005; **35**(10): 1288–94. [PubMed Abstract](#) | [Publisher Full Text](#)
98. Aminuddin F, Hackett TL, Stefanowicz D, *et al.*: Nitric oxide synthase polymorphisms, gene expression and lung function in chronic obstructive pulmonary disease. *BMC Pulm Med.* 2013; **13**: 64. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 10 May 2021

<https://doi.org/10.5256/f1000research.55513.r81755>

© 2021 Park S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sang Won Park

Department of Pharmacology, College of Medicine, Institute of Health Sciences, Gyeongsang National University, Jinju, South Korea

The reviewer's concerns have been addressed in the response and the last sentence ("We only tried to identify....gene-gene interaction.") should be included in the manuscript to avoid the readers misunderstood.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Acute kidney injury, preclinical study,

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 22 March 2021

<https://doi.org/10.5256/f1000research.55513.r81754>

© 2021 Zhang H. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hongliang Zhang

Department of Life Sciences, National Natural Science Foundation of China, Beijing, China

The reviewer's concerns have been adequately addressed.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: nephrology, neurology, neuroimmunology, neuroimaging, neuroscience

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 19 Apr 2021

Jonny Fajar

We are very grateful for the invaluable advice.

Competing Interests: No competing interests were disclosed.

Version 1

Reviewer Report 10 August 2020

<https://doi.org/10.5256/f1000research.25378.r68104>

© 2020 Park S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sang Won Park

¹ Department of Pharmacology, College of Medicine, Institute of Health Sciences, Gyeongsang National University, Jinju, South Korea

² Department of Pharmacology, College of Medicine, Institute of Health Sciences, Gyeongsang National University, Jinju, South Korea

This study performed a meta-analysis for an association study of NOS3 and klotho polymorphisms with CKD and age-related cognitive impairment (ACI). Several NOS3 and klotho polymorphic nucleotide sites were analyzed in 48 selected papers. The correlation was found only in NOS3 G894T with ACI. On the other hand, the correlation was found in NOS 4b4a, NOS3 G894T, and KL G395A with CKD. The authors conclude that NOS3 G894T has a crucial role in the pathogenesis of both CKD and ACI. I have a major concern as follows.

The purpose of this paper is not clear. Which is to reveal common polymorphisms in ACI and CKD to associate these two pathologies, to find polymorphisms correlated in CKD and aging, by using ACI as a marker of aging, or other purposes? However, ACI is not a good marker of aging in a meta-analysis because ACI has pathological complexity. According to the purpose, the parameter selection of polymorphic genes should be different. NOS3 functions in the cardiovascular system and the NOS3 polymorphisms are susceptible to diseases, such as hypertension, atherosclerosis, stroke, and other complications. Klotho functions in the endocrine FGF-mediated metabolic processes, such as regulating insulin secretion, feeding, and renal reabsorption of calcium and phosphate; therefore, it is associated with diabetes, CKD, and other metabolic disorders. In this regard, a meta-analysis to reveal the correlation between NOS3 and ACI should be performed

separately to the meta-analysis to reveal the correlation between Klotho with CKD. Without a clear purpose, correlation studies of NOS3 and Klotho in both ACI and CKD are not clinically important. Please clarify your purpose of the study and revise your introduction and conclusions with appropriate references. You may be required additional meta-analysis on other gene polymorphisms related to ACI and CKD.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Partly

Are sufficient details of the methods and analysis provided to allow replication by others?

Partly

Is the statistical analysis and its interpretation appropriate?

Partly

Are the conclusions drawn adequately supported by the results presented in the review?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Acute kidney injury, preclinical study,

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Mar 2021

Jonny Fajar

Our study aimed to perform a meta-analysis concerning the role of NOS and klotho gene polymorphisms in the case of age-related cognitive impairment and CKD. In our paper, we only tried to identify the potential SNPs having the role in the development of CKD and the development of age related cognitive impairment. We did not propose the possible causal correlation between age related cognitive impairment and CKD. They are two distinct condition. We only tried to identify the similar SNPs between CKD and age related to cognitive impairment, and in the future, this similarity might be used in the concept of gene-gene interaction.

Competing Interests: There is no coompeting interest.

Reviewer Report 06 July 2020

<https://doi.org/10.5256/f1000research.25378.r66026>

© 2020 Zhang H. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hongliang Zhang

¹ Department of Life Sciences, National Natural Science Foundation of China, Beijing, China

² Department of Life Sciences, National Natural Science Foundation of China, Beijing, China

The authors performed a meta-analysis to assess the role of NOS and klotho single nucleotide polymorphisms (SNPs) in the pathogenesis of CKD and age-related cognitive impairment. They identified SNPs potentially involved in the pathogenesis of age-related cognitive impairment and CKD. They concluded that *NOS3* G894T gene polymorphism has a crucial role in the pathogenesis of both CKD and age-related cognitive impairment. Overall, the study is well designed and conducted. The PRISMA checklist was well implemented.

Major concern:

1. A hypothesis is missing and validation is lacking. Association does not necessarily mean a causal relationship. Confounding factors, mediators, and compensatory factors can be implicated in the role of NOS and klotho single nucleotide polymorphisms (SNPs) in the pathogenesis of CKD and age-related cognitive impairment.
2. The definition and diagnostic criteria seem lacking for age-related cognitive impairment. Of note is that age-related cognitive impairment is not a disease. Ref 13 fails to give a definition.

Minor points:

1. "and being of low-quality (two)." in the paper selection should be specified.
2. "a candle in the darkness" is kind of exaggerated. It is simply a meta-analysis. The data should not be over-interpreted.
3. The language should be polished. "frightening" appears frightening in scientific writings. "13 papers were also excluded because of review(s)" should be rephrased. Please use "we found that....." instead of "our results found that.....".
4. "For age-related cognitive impairment, we identified three SNPs available for meta-analysis calculation, such as: *NOS3* G894T, *NOS3* T786C, and *KL* G-395A." can be rephrased to "For age-related cognitive impairment, we identified three SNPs available for meta-analysis calculation, including *NOS3* G894T, *NOS3* T786C, and *KL* G-395A."

Are the rationale for, and objectives of, the Systematic Review clearly stated?

No

Are sufficient details of the methods and analysis provided to allow replication by others?

Partly

Is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are the conclusions drawn adequately supported by the results presented in the review?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: nephrology, neurology, neuroimmunology, neuroimaging, neuroscience

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Mar 2021

Jonny Fajar

1. A hypothesis is missing and validation is lacking. Association does not necessarily mean a causal relationship. Confounding factors, mediators, and compensatory factors can be implicated in the role of NOS and klotho single nucleotide polymorphisms (SNPs) in the pathogenesis of CKD and age-related cognitive impairment.

Response: the potential confounding factors, mediators, and compensatory factors that might affect the final findings of our study have been provided in the limitations.

2. The definition and diagnostic criteria seem lacking for age-related cognitive impairment. Of note is that age-related cognitive impairment is not a disease. Ref 13 fails to give a definition.

Response: In the second paragraph of introduction, we did not provide the definition and diagnostic criteria of age-related cognitive impairment. We only described the problems in the context of aging and age related cognitive impairment.

3. " and being of low-quality (two)." in the paper selection should be specified.

Response: We have revised the sentence.

4. "a candle in the darkness" is kind of exaggerated. It is simply a meta-analysis. The data should not be over-interpreted.

Response: We have revised the sentence.

5. The language should be polished. "frightening" appears frightening in scientific writings. " 13 papers were also excluded because of review(s)" should be rephrased. Please use "we found that..... " instead of "our results found that..... ".

Response: We have revised the sentence.

6. "For age-related cognitive impairment, we identified three SNPs available for meta-analysis calculation, such as: NOS3 G894T, NOS3 T786C, and KL G-395A." can be rephrased to "For age-related cognitive impairment, we identified three SNPs available for meta-analysis calculation, including NOS3 G894T, NOS3 T786C, and KL G-395A."

Response: We have revised the sentence.

Competing Interests: There is no competing interest.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research